对选择的黄类化合物在PD-1/PD-L1通路上的结合亲缘关系和阻断作用的分子洞察力
Yan Guo1, Jinchang Tong1, Jianhuai Liang2
1College of Food Science, Shanxi Normal University Taiyuan 030031 China xjg71@163.com.
RSC advances
|August 19, 2024
概括
像奎尔丁这样的黄类化合物有效地与PD-L1二元体结合,阻断PD-1/PD-L1相互作用. 这表明,黄醇对开发针对这种途径的新型癌症免疫疗法充满希望.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 计算化学计算化学
背景情况:
- PD-1/PD-L1通路是免疫反应的关键调节者,也是癌症免疫治疗的目标.
- 黄酸是具有潜在治疗性能的天然化合物.
研究的目的:
- 为了研究阿皮基宁,凯姆菲罗尔和奎尔塞丁与PD-L1二分体的结合机制.
- 评估这些黄类药物作为PD-1/PD-L1相互作用的抑制剂的潜力.
主要方法:
- 分子建模技术 (例如,结合自由能计算,动态交叉相关矩阵分析).
- 使用酶相关免疫吸收试验 (ELISA) 进行实验验证.
主要成果:
- 黄类药物对PD-L1二元体具有强烈的结合,结合亲和力依次:奎尔塞丁 > 凯姆菲罗尔 > 亚皮基宁.
- 确定了关键的结合残留物 (Ile54,Tyr56,Met115,Ala121,Tyr123) 和结合领域 (C-,F-,G片).
- 黄类药物有效地阻断PD-1/PD-L1相互作用,而黄类药物显示出比黄类药物更大的抑制活性.
结论:
- 黄类,特别是黄类,可以有效地向和抑制PD-1/PD-L1通路.
- 这些发现支持开发用于癌症免疫治疗的基于黄类新疗法.
相关概念视频
02:18The Equilibrium Binding Constant and Binding Strength
12.8K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
12.8K
02:40Ligand Binding Sites
12.8K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.8K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K